Preparations for Pfizer Inc.'s launch of Celltrion Inc.'s Remicade biosimilar in the US continue, although are not ready for execution yet.
Pfizer told the Pink Sheet Oct. 6 that it still plans to launch Inflectra (infliximab-dyyb) this year, even though the six-month notification period has expired and the company can launch...